SMITHS FALLS, Ont. - Canopy Growth Corp. has signed a deal to buy a German company that specializes in cannabinoid-based medical therapies used by European physicians for roughly $342.9 million.
Under the deal, the Ontario-based company has acquired C3 Cannabinoid Compound Co.
C3's main medicinal offering is dronabinol, a compound with standardized concentrations of THC (tetrahydrocannabinol), the main psychoactive compound in cannabis.
Dronabinol is available in Austria, Denmark and Germany.
C3 has two manufacturing facilities specializing, respectively, in natural extraction and synthetic cannabinoid production.
The company's senior management team is expected to continue with the business.
Bagikan Berita Ini
Related Posts :
Quebec restaurant ordered to reinstate waitress allegedly fired for not smiling- Condos, towns still in demand in Vancouver but detached sales down: real estate board
- Toronto market posts triple-digit decline, U.S. stock markets also fall
- Dow plunges over 500 points, TSX down over 200
- Dow plunges over 400 points, TSX down nearly 200
0 Response to "Canopy Growth buys German medical cannabis company for $343M"
Post a Comment